• Revenue in the first half of 2024 reached 60.7382 million yuan, an increase of 44.24% year on year
• R&D investment reached 166.1674 million yuan, up 72.91% year on year; R&D investment accounted for 273.58% of revenue, an increase of 45.37 percentage points over the same period last year

SHANGHAI, September 2, 2024/PRNewswire/ -- On August 29, 2024, Shanghai Mengke Pharmaceutical Co., Ltd. (“Mengke Pharmaceutical”, 688373.SH) disclosed its report for the first half of 2024. During the reporting period, the company achieved revenue of 60.7382 million yuan, an increase of 44.24% year on year; R&D investment reached 166.1674 million yuan, up 72.91% year on year; R&D investment accounted for 273.58% of revenue, an increase of 45.37 percentage points over the same period last year.

The commercialization process has been steadily promoted, and business performance has increased dramatically

The company's first commercial product, contizolamide tablets, is a new generation of oxazolidinone antimicrobials independently designed and developed by the company. It can be used to treat infections caused by multiple 688373 drug-resistant gram-positive bacteria.

Contizolamide tablets have been fully rolled out in the domestic market, covering 533 hospitals across the country, and have achieved formal admission and batch procurement in 143 hospitals. During the reporting period, the company achieved revenue of 60.7382 million yuan, an increase of 44.24% over the previous year.

With their good safety and efficacy, contizolamide tablets have accumulated a large number of successful real-world cases in the treatment of complex skin and soft tissue infections, bloodstream infections, and drug-resistant tuberculosis, and have been highly recognized by clinicians and patients. During the reporting period, a total of 16 evidence-based medical achievements and academic construction achievements were obtained.

The research pipeline progresses in an orderly manner, and continuously consolidates the core competitiveness of the enterprise

In addition to contizolamide tablets, the core product that has been commercialized, the company is also actively promoting clinical trials and early R&D of various products under development.

The company continues to expand the scope of application of contezolamide. After the clinical application in the adult field was widely verified, it accelerated phase II clinical trials of contezolamide tablets to treat complex skin tissue infections between the ages of 6 and 17. It is also actively promoting phase III clinical trials of MRX-4. MRX-4 is a water-soluble precursor to contizolamide tablets that exerts curative effects in the body. It is expected that after approval for marketing, it can provide more convenience in medication use for critically ill patients and patients unsuitable for oral administration, greatly expanding usage scenarios.

At the same time, MRX-8, which is used to treat multiple drug-resistant gram-negative bacterial infections, has also made encouraging progress. During the reporting period, MRX-8 China's phase I clinical trial was successfully completed and reached the expected goals, marking that MRX-8 has taken a key step towards becoming a safe and effective new antimicrobial drug.

The company is also continuing to advance clinical trials of MRX-5 against mycobacterial infections (NTM). The Australian Phase I clinical trial has completed all single-dose climbing groups, food effect groups, and two groups of multiple-dose climbing groups, and it is expected that research will be completed this year.

In addition, the company will continue to promote early research and development of peptide drug conjugates and antibody drug conjugates to meet clinical needs in the treatment of kidney disease and tumors. At present, peptide drug conjugates and antibody drug conjugate pipelines have completed phased pharmacogenicity studies and applied for a number of patents.

In the future, the company will also continue to consolidate its core competitiveness and strive to maintain its leading position in the industry based on three core technologies suited to its own R&D characteristics, including drug molecular design and discovery technology, metabolism-based drug design and optimization technology, and targeted treatment platform technology.

About Mengke

Established in 2007, it is an innovative biomedical enterprise centered on treating infectious diseases, with global independent intellectual property rights and international competitiveness. It is committed to discovering, developing and commercializing innovative drugs that do not meet clinical needs. Since its inception, the company has been adhering to the concept of “seeking good results with good medicine”, focusing on the increasingly serious problem of bacterial drug resistance around the world, solving clinical problems and differentiated innovation as its core competitiveness. The goal is to provide more effective and safer treatment options for the most common and serious clinically resistant bacterial infections. For more information, please visit the official website of Mengke Pharmaceuticals or subscribe to Mengke Pharmaceuticals China's official WeChat account.